Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
February 04 2020 - 8:00AM
Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of
therapeutics that target galectin proteins, today announced that
Dr. Harold H. Shlevin, the Company’s President and CEO, will
present at the 3rd Global NASH Congress 2020 at the London Heathrow
Marriott on Tuesday, February 11, at 3:00 p.m. (15:00) local time.
In his presentation, titled “Clinical development of belapectin
(GR-MD-02), a galectin-3 inhibitor, in treatment of NASH
cirrhosis,” Dr. Shlevin will discuss how Galectin-3 inhibition has
been shown to be central to the fibrotic process involved in the
development of NASH-related cirrhosis, and how belapectin
(GR-MD-02), the company’s galectin-3 inhibitor, has been
demonstrated in a Phase 2b trial to decrease hepatic venous
pressure gradient in compensated NASH cirrhotic patients without
varices at baseline. Dr. Shlevin will also outline how the results
of Galectin’s Phase 2 clinical trial have provided guidance for an
adaptively designed Phase 3 trial. This Phase 3 trial is designed
with interim analysis aimed at reaffirming the efficacy early on
and includes various adaptations to sample size, dose and duration
to maximize the likelihood of success of the overall study.
Additionally, he will discuss aspects of the trial designed to
enhance patient enrollment and retention over the two years
duration of treatment.
In addition to the presentation, Dr. Shlevin will also chair the
morning session of the Metabolic Syndrome, Diabetes and NAFLD
Symposium on Monday, February 10, beginning at 11:40 a.m. local
time.
The 3rd Global NASH Congress 2020, featuring over 60 individual
talks, panels, and roundtable discussions, was designed to
facilitate collaboration between the multiple communities working
on NASH, NAFLD, obesity, diabetes, and metabolic syndrome.
About Galectin TherapeuticsGalectin
Therapeutics is developing promising carbohydrate-based therapies
for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, which are key
mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer.Additional
information is available at www.galectintherapeutics.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
relate to future events or future financial performance and use
words such as “may,” “estimate,” “could,” “expect” and others. They
are based on management’s current expectations and are subject to
factors and uncertainties that could cause actual results to differ
materially from those described in the statements. These statements
include those regarding the hope that Galectin’s development
program for belapectin (GR-MD-02) will lead to the first therapy
for the treatment of NASH with cirrhosis and those regarding the
hope that our lead compounds will be successful in cancer
immunotherapy. Factors that could cause actual performance to
differ materially from those discussed in the forward-looking
statements include, among others, the Company’s Phase 3 clinical
trial for the treatment of NASH, now in the final planning stages,
and any future clinical studies, including those in connection with
cancer immunotherapy, may not proceed and may not produce positive
results in a timely fashion, if at all, and could prove
time-consuming and costly; plans regarding development, approval,
and marketing of any of Galectin’s drugs are subject to change at
any time based on the changing needs of the Company as determined
by management and regulatory agencies; Galectin may not be
successful in developing effective treatments and/or obtaining the
requisite approvals for the use of belapectin; manufacturing of
drug product now in scale-up may not be successful or meet
regulatory expectations; regardless of the results of any of its
development programs, Galectin may be unsuccessful in developing
partnerships with other companies or raising additional capital
that would allow it to further develop and/or fund any studies or
trials. Galectin has incurred operating losses since inception, and
its ability to successfully develop and market drugs may be
impacted by its ability to manage costs and finance continuing
operations. For a discussion of additional factors impacting
Galectin’s business, see the Company’s Annual Report on Form 10-K
for the year ended December 31, 2018, and subsequent filings with
the SEC. You should not place undue reliance on forward-looking
statements. Although subsequent events may cause its views to
change, management disclaims any obligation to update
forward-looking statements.
Company Contact:Jack Callicutt, Chief Financial
Officer(678) 620-3186ir@galectintherapeutics.com
Media Contact:Gregory FCALexi Burchmore,
Account Supervisor(215) 297-3607lexib@gregoryfca.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024